COVID-19 portal | Vitamin D | CDC | Vaccine | Keto | W8MD Diet

WikiMD is world's largest health encyclopedia with
28,544 pages, 3,991,367 edits & 34,287,015 views.

Unbiased health & wellness info for free & for all!


From WikiMD
Jump to navigation Jump to search




Acalabrutinib is a medication used to treat a type of non-Hodgkin lymphoma known as mantle cell lymphoma in those had previously been treated with another therapy.



  • Acalabrutinib is a drug used to treat mantle cell lymphoma in patients who have already received at least one other treatment.
  • It is also being studied in the treatment of other types of cancer.
  • Acalabrutinib blocks a protein called Bruton’s tyrosine kinase (BTK) , which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called Calquence.

Information about Acalabrutinib

Acalabrutinib is an oral inhibitor of Bruton’s tyrosine kinase that is used in the therapy of B cell malignancies including refractory mantle cell lymphoma.   


Liver safety of Acalabrutinib

Acalabrutinib has not been associated with serum enzyme elevations during therapy or with cases of idiosyncratic acute liver injury, but has been linked to cases of reactivation of hepatitis B

Mechanism of action of Acalabrutinib

  • Acalabrutinib (a kal" a broo' ti nib) is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK), which is an essential component in the B cell receptor signaling pathway. 
  • Inhibition of this pathway prevents B cell activation, differentiation and proliferation. 
  • Deficiency of BTK is the cause of X linked (Bruton’s) agammaglobulinemia, and B cell receptor signaling through BTK has been shown to be critical for proliferation and survival of malignant B lymphocytes in mantle cell lymphoma and CLL. 
  • Unlike ibrutinib, another BTK inhibitor, acalabrutinib has a high degree of specificity for BTK and has little or no activity against EGFR and other tyrosine kinases

FDA approval information for Acalabrutinib

Acalabrutinib was approved for use in the United States as therapy for refractory mantle cell lymphoma in 2017 and is under evaluation in other malignancies such as chronic lymphoid leukemia (CLL), pancreatic cancer and non-small cell lung cancer

Dosage and administration for Acalabrutinib

Acalabrutinib is available in capsules of 100 mg under the brand name Calquence.  The recommended dose is 100 mg once daily. 

Flower cell in mantle cell lymphoma
Flower cell in mantle cell lymphoma

Side effects of Acalabrutinib

Side effects are common, but usually mild-to-moderate in severity; they include:

Uncommon, but potentially serious side effects include:

Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ


Cost and Coupons - Acalabrutinib

Reviews for Acalabrutinib

Learn more about Acalabrutinib

Latest research (Pubmed)


External links


WikiMD needs you!

This WikiMD article Acalabrutinib is a stub.
If you are a healthcare professional familiar with the topic Acalabrutinib, or
A subject matter expert or authority on Acalabrutinib, you can help us.
About | Mission | Paid editors welcome!

Acalabrutinib is part of WikiMD's Physician reviewed^ articles available 4free, 4all, 4ever!
Medicine: Health - Encyclopedia‏‎‏‎ - Topics‏‎ -‏‎ Diseases‏‎ - Cancer - Rare diseases - Random Page Navigation: Drugs - Wellness - Obesity‏‎ - Diet - Ketogenic diet - W8MD weight loss diet - Editors: Recently Edited Pages - Alphabetical Order - Sponsors - USMLE The content on or accessible through WikiMD is for informational purposes only. WikiMD is not a substitute for professional medical advice. ^See full Disclaimers
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP*